XASXVTI
Market cap1mUSD
Dec 23, Last price
0.05AUD
1D
-1.96%
1Q
-54.55%
IPO
-99.89%
Name
Visioneering Technologies Inc
Chart & Performance
P/E
—
P/S
0.20
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
74.43%
Rev. gr., 5y
21.36%
Revenues
9m
+19.01%
Net income
-3m
L-41.05%
CFO
-5m
L-7.00%
Earnings
May 23, 2025
Profile
Visioneering Technologies, Inc., a medical device company, engages in the design, manufacture, sale, and distribution of contact lenses in North America, Europe, and the Asia-Pacific. The company's flagship product comprises NaturalVue, a multifocal contact lens for adults with presbyopia and children with myopia. Visioneering Technologies, Inc. was incorporated in 2008 and is headquartered in Alpharetta, Georgia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||
Revenues | 8,670 19.01% | 7,285 1.83% | 7,154 40.14% | |||||
Cost of revenue | 10,476 | 14,431 | 15,134 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,806) | (7,146) | (7,980) | |||||
NOPBT Margin | ||||||||
Operating Taxes | 4 | 6 | 5 | |||||
Tax Rate | ||||||||
NOPAT | (1,810) | (7,152) | (7,985) | |||||
Net income | (3,451) -41.05% | (5,854) 150.81% | (2,334) -74.74% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 1,643 | 16,601 | ||||||
BB yield | -88.20% | |||||||
| Debt | ||||||||
Debt current | 119 | 314 | 143 | |||||
Long-term debt | 193 | 1,523 | 2,753 | |||||
Deferred revenue | ||||||||
Other long-term liabilities | 132 | 213 | 9 | |||||
Net debt | (2,687) | (3,118) | (8,089) | |||||
| Cash flow | ||||||||
Cash from operating activities | (5,422) | (5,830) | (10,665) | |||||
CAPEX | (4) | (19) | ||||||
Cash from investing activities | 2,769 | (1,842) | (19) | |||||
Cash from financing activities | 2,475 | (43) | 16,601 | |||||
FCF | (987) | (8,276) | (9,374) | |||||
| Balance | ||||||||
Cash | 2,999 | 4,955 | 10,985 | |||||
Long term investments | ||||||||
Excess cash | 2,566 | 4,591 | 10,627 | |||||
Stockholders' equity | 5,758 | 6,294 | 10,045 | |||||
Invested Capital | 6,185 | 3,439 | 2,893 | |||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | 34,852 | 26,580 | 21,510 | |||||
Price | 0.40 -54.29% | 0.88 -65.00% | ||||||
Market cap | 10,632 -43.51% | 18,822 -3.34% | ||||||
EV | 7,514 | 10,733 | ||||||
EBITDA | (1,806) | (7,122) | (7,829) | |||||
EV/EBITDA | ||||||||
Interest | 83 | 296 | 322 | |||||
Interest/NOPBT | ||||||||